Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Ablynx and Merck Serono enter into an agreement to co-discover and co-develop Nanobodies®

Abstract:
Ablynx and Merck Serono to equally contribute to discover and develop Nanobodies® against two targets in oncology and immunology and equally share the resulting profits

Ablynx and Merck Serono enter into an agreement to co-discover and co-develop Nanobodies®

Ghent, BELGIUM | Posted on September 4th, 2008

Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, today announced that it has entered into an agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, to co-discover and co-develop Nanobodies® against two targets in oncology and immunology. The agreement includes an upfront cash payment to Ablynx of EUR 10 million.

Nanobodies® are a new class of therapeutic proteins that contain the unique structural and functional properties of naturally-occurring single domain antibodies. The partners will collaborate to research and develop Nanobody®-based therapeutics against two disease targets exploiting some of the key benefits Nanobodies® have over conventional antibodies and other fragments.

Under the terms of the agreement, both companies will equally share all research and development costs. Should Ablynx contribute equally to each program, it will be eligible to receive fifty percent of the resulting profits. In addition, Ablynx will have an option to opt-out partly or fully during the research and development programs, in which case the company would be eligible to receive either a reduced profit share, in the case of a partial opt-out, or milestones and royalties on potential sales, in the case of a full opt-out. Total development and commercial milestones, depending on the point of opt-out by Ablynx, could reach up to EUR 325 million should a product be approved in multiple indications in all major markets.

"This collaboration reinforces our commitment to deliver innovative treatments in areas of high unmet medical needs," said Dr Bernhard Kirschbaum, Executive Vice President Research of Merck Serono. "We believe that Nanobodies® have the potential to provide innovative drugs combining the best features of monoclonal antibodies and small molecules, and we look forward to working with Ablynx."

####

For more information, please click here

Contacts:
For more information, please contact:
College Hill Life Sciences - for UK/International media enquiries:
Sue Charles, Justine Lamond, John McIntyre
t: +44 (0)20 7866 7857
f: +44 (0)20 7866 7900
e:


Ablynx:
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
e:

Eva-Lotta Allan
Chief Business Officer
t: +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
e:

Copyright © Marketwire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Feynman Prize Winners Announced! April 26th, 2015

New ASTM Standards Will Help Educate Present and Future Nanotechnology Workforces April 26th, 2015

Heat makes electrons’ spin in magnetic superconductors April 26th, 2015

QD Vision Wins 2015 Bronze Edison Award for Color IQ™ Quantum Dot Technology April 26th, 2015

Nanomedicine

Northwestern scientists develop first liquid nanolaser: Technology could lead to new way of doing 'lab on a chip' medical diagnostics April 25th, 2015

Nanotech-enabled moisturizer speeds healing of diabetic skin wounds: Spherical nucleic acids silence gene that interferes with wound healing April 24th, 2015

Fast and accurate 3-D imaging technique to track optically trapped particles April 24th, 2015

A silver lining: UCSB researchers cradle silver nanoclusters inside synthetic DNA to create a programmed, tunable fluorescent array April 23rd, 2015

Announcements

Feynman Prize Winners Announced! April 26th, 2015

New ASTM Standards Will Help Educate Present and Future Nanotechnology Workforces April 26th, 2015

Heat makes electrons’ spin in magnetic superconductors April 26th, 2015

QD Vision Wins 2015 Bronze Edison Award for Color IQ™ Quantum Dot Technology April 26th, 2015

Alliances/Partnerships/Distributorships

How can you see an atom? (video) April 10th, 2015

FibeRio and VF Corporation Form Strategic Partnership to Lead the Apparel and Footwear Markets in Nanofiber Technology April 8th, 2015

UK National Graphene Institute Selects Bruker as Official Partner: World-Leading Graphene Research Facility Purchases Multiple Bruker AFMs April 7th, 2015

NXP and GLOBALFOUNDRIES Announce Production of 40nm Embedded Non-Volatile Memory Technology: Co-developed technology to leverage GLOBALFOUNDRIES 40nm process technology platform March 24th, 2015

Research partnerships

Heat makes electrons’ spin in magnetic superconductors April 26th, 2015

Pseudoparticles travel through photoactive material: KIT scientists measure important process in the conversion of light energy -- publication in Nature Communications April 24th, 2015

Electron spin brings order to high entropy alloys April 23rd, 2015

Surface matters: Huge reduction of heat conduction observed in flat silicon channels April 23rd, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project